Category: 24211-55-0

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.24211-55-0,(S)-Piperidin-3-ol,as a common compound, the synthetic route is as follows.

4-Chloro-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine (43 mg, 0.10 mmol) prepared in step 4 of Example 1 was dissolved in 5 mL of tetrahydrofuran, and (S)-3-hydroxypiperidine (12 mg, 0.12 mmol) and sodium carbonate (16 mg, 0.15 mmol) were added. The mixture was heated under reflux for 16 h. The resultant solution was filtered, and the filtrate was purified by column chromatography to give the title compound. 1H NMR (500MHz, DMSO-d6): delta 10.70 (br, 1H), 8.55-8.66 (m, 3H), 8.26-8.33 (m, 1H), 8.08-8.11 (m, 1H), 7.85 -7.96 (m, 1H), 4.97-4.98 (m, 1H), 4.16-4.49 (m, 2H), 3.26-3.60 (m, 3H), 1.83-1.92 (m, 2H), 1.51-1.54 (m, 2H).ES: m/z 486.1 [M+H]+., 24211-55-0

24211-55-0 (S)-Piperidin-3-ol 6950221, apiperidines compound, is more and more widely used in various fields.

Reference£º
Patent; Nanjing Sanhome Pharmaceutical Co., Ltd.; WANG, Yong; ZHAO, Liwen; LIU, Xiaorong; ZHANG, Yan; HUANG, Dandan; JIANG, Chunhuan; SHI, Xinsheng; GU, Hongfeng; PANG, Silin; HAI, Wei; GE, Bingyang; (71 pag.)EP3489230; (2019); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.24211-55-0,(S)-Piperidin-3-ol,as a common compound, the synthetic route is as follows.

2,3′-difluoro-4′-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methoxy)biphenyl-4-carboxylic acid (0.04 g, 0.10 mmol) and (S)-piperidin-3-ol (0.02 g, 0.19 mmol) were dissolved in DMF 2 mL. DIPEA (0.08 mL, 0.48 mmol), EDCI (0.04 g, 0.19 mmol) and HOBt (0.03 g, 0.19 mmol) were added thereto slowly, following with stirring at 60 C. for 3 hours. After the completion of the reaction, excess amount of water was added to the reaction mixture. The resulting precipitate was filtered, and dissolved in CH2Cl2. The solution was concentrated under reduced pressure. The obtained concentrate was purified by column chromatography (40 g ISCO silica gel cartridge, 0-20% MeOHCH2Cl2) to yield the title compound as light-yellow solid (0.02 g, 42%). 1H NMR (400 MHz, CDCl3) delta 7.40 (t, 1H, J=5.8 Hz), 7.29-7.21 (m, 4H), 6.99 (t, 1H, J=6.4 Hz), 3.88 (d, 2H, J=4.6 Hz), 3.78-3.27 (m, 4H), 2.97 (d, 2H, J=8.2 Hz), 2.45 (s, 1H), 2.40 (s, 1H), 2.16 (t, 2H, J=8.5 Hz), 1.91-1.65 (m, 7H), 1.45-1.23 (m, 8H); MS (ESI) mz 505 (M++H)

24211-55-0, The synthetic route of 24211-55-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; CHONG KUN DANG PHARMACEUTICAL CORP.; Lee, ChangSik; Jang, TaegSu; Choi, DaeKyu; Ko, MooSung; Kim, DoHoon; Kim, SoYoung; Min, JaeKi; Kim, WooSik; Lim, YoungTae; US2015/166480; (2015); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem